Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review

Background: Nowadays, the new coronavirus-induced severe acute respiratory syndrome (COVID-19) outbreak was primarily stated in December 2019. Three months later, Director-General of World Health Organization, avowed COVID-19 a global pandemic. Gathered evidence discloses that coagulation is repeatedly seen COVID-19, and incidence higher cases. The worsening lung functions coagulopathy are some most significant poor prognostic criteria outcome COVID-19. pragmatic patients hospitalized with (COVID-19 associated coagulopathy) categorized by increased level D-dimer fibrinogen/fibrin degradation products. They interrelated severity This elevation will aid arrangement consistent disease management. These parameters can point to prognosis. Coagulopathy mainly affects immobilized patients, those critical care units, who have extra risk factors predispose coagulopathy, for instance, inflammatory conditions hypoxia. exact pathogenesis hypercoagulability unwell understood. signs suggest COVID?19 an evolving phenomenon which endothelial damage, platelet aggregation, augmented innate immune response, other measures as systemic inflammation favoring would divide up this disease. Understanding pathophysiology related crucial suitable treatment monitoring these patients. Encouraging interest potential uses anticoagulation particularly use heparin has benefit over anticoagulants due its anticoagulant role, anti-inflammatory, potentially anti-viral properties.